Active Research Studies: Gastric Cancer
Comprehensive Cancer Centers is currently running the following clinical research study for gastric cancers.
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
Study#: i3361
Contact Us: For information about this clinical study, Email Us.
A Phase 3, multicenter, randomized, open-label, study evaluating the efficacy and safety of nanvuranlat in patients with previously treated advanced biliary tract cancer.
Study#: Independent
Contact Us: For information about this clinical study, Email Us.
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally dvanced or Metastatic Gastroesophageal Junction and Gastric Cancer.
Study#: i3298
Contact Us: For information about this clinical study, Email Us.